Abcellera Biologics is trading at $11.84, down 4.56%, with no newly reported company-specific catalyst identified for August 28, 2026.
- Recent coverage remains focused on positive ABCL635 Phase 2 results and the previously priced $200 million offering, both announced earlier in August.
- The broader market is mixed rather than sharply lower, so the immediate cause remains unclear.